Antithrombotics today

Česká verzia

Authors: Miloslava Matýšková; Jana Michalcová; Miroslav Penka
Authors place of work: Oddělení klinické hematologie FN Brno, pracoviště Bohunice
Published in the journal: Vnitř Lék 2018; 64(5): 565-574
Category:

Summary

Over the last 10 years some new drugs affecting blood clotting – antithrombotics – were invented. For more than half a century only warfarin and heparin were available. A better understanding of the pathways involved in activation of blood clotting, the links between these systems, and the impact of thrombosis on inflammation, have led to identification of new targets and development of new drugs, especially new antiplatelet drugs and anticoagulants. With the advent of new drugs into clinical practice, treatment options of thrombotic complications are expanding. However, it is always necessary to get familiar with the drug and its properties and to know its limitations. This is the only way to offer patients the best practices.

Key words:

anticoagulant – antithrombotic – Direct Oral AntiCoagulant (DOAC) – laboratory monitoring – Low-Molecular-Weight Heparins (LMWH) – New Oral Anticoagulants/Non-vitamin K Oral AntiCoagulants (NOAC) – unfractionated heparin (UFH) – warfarin

Zdroje

Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 2008; 141(6): 757–763. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2141.2008.07119.x>.
Shampo MA, Kyle RA. J. Erik Jorpes – Pioneer in the Identification and Clinical Applications of Heparin. Mayo Clin Proc 1997; 72(11): 1056. Dostupné z DOI: <http://dx.doi.org/10.1016/S0025–6196(11)63547–7>.
Bauer KA, Hawkins PCP, Petitou M et al. Fondaparinux, a Synthetic Pentasaccharide: The First in a New Class of Antithrombotic Agents – The Selective Factor Xa Inhibitors. Cardiovasc Drug Rev 2002; 20(1): 37–52.
Markwardt F. Historical Perspective of the Development of Thrombin Inhibitors. Pathophysiol Haemost Thromb 2002; 32(Suppl 3): S15-S22. Dostupné z DOI: <http://dx.doi.org/10.1159/000069104>.
Yeh CH, Fredenburgh JC, Weitz JI. Oral direct factor Xa inhibitors. Circ Res 2012; 111(8): 1069–1078. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.112.276741>.
Kearon C, Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease. CHEST Guideline and Expert Panel Report. Chest 2016; 149(2): 315–352. Dostupné z DOI: <http://dx.doi.org/10.1016/j.chest.2015.11.026>.
Barnes GD, Ageno W, Ansell J et al. For the subcommittee on the control of anticoagulation. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13(6): 1154–1156. Dostupné z DOI: <http://dx.doi.org/10.1111/jth.12969>. Erratum in Corrigendum [J Thromb Haemost. 2015].
Nutescu EA, Burnett A, Fanikos J et al. Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis 2016; 41(1): 15–31. Dostupné z DOI: <http://dx.doi.org/10.1007/s11239–015–1314–3>.
Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008; 99(5): 819–829. Dostupné z DOI: <http://dx.doi.org/10.1160/TH07–11–0693>.
Escolar G, Bozzo J, Maragall S. Argatroban: A direct thrombin inhibitor with reliable and predictable anticoagulant actions. Drugs Today 2006; 42(4): 223. Dostupné z DOI: <http://dx.doi.org/10.1358/dot.2006.42.4.953588>.
Heparin-Leciva. SPC. Dostupné z WWW: <http://www.sukl.cz/modules/medication/detail.php?code=0091915&tab=texts>.
12.Warfarin Orion. SPC. Dostupné z WWW: <http://www.sukl.cz/download/spc/SPC3811.pdf>.
Fraxiparine. SPC. Dostupné z WWW: <http://www.sukl.cz/modules/medication/detail.php?code=0213487&tab=text>.
Souhrn údajů o přípravku Arixtra. [The European Medicines Agency]. Dostupné z WWW: <http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000403/WC500027746.pdf>.
Souhrn údajů o přípravku Pradaxa. [The European Medicines Agency]. Dostupné z WWW: <http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf>.
Souhrn údajů o přípravku Xarelto. [The European Medicines Agency]. Dostupné z WWW: <http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf>.
Souhrn údajů o přípravku Eliquis. [The European Medicines Agency]. Dostupné z WWW: <http://www.ema.europa.eu/docs/cs_CZ/document_librar/EPAR_-_Product_Information/human/002148/WC500107728.pdf >.
Souhrn údajů o přípravku Lixiana. [The European Medicines Agency]. Dostupné z WWW: <http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf>.
Kvasnička J, Penka M, Kvasnička T et al. Doporučení České společnosti pro trombózu a hemostázu České lékařské společnosti J. E. Purkyně pro bezpečnou léčbu novými perorálními antikoagulancii (NOAC) – dabigatran etexilátem, apixabanem a rivaroxabanem. Vnitř Lék 2015; 61(6): 537–546.
Robertson L, KestevenP, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database Syst Rev 2015; (6): CD010956. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD010956.pub2>.
Michalcová J, Penka, M, Buliková A et al. Nová – přímá perorální antikoagulancia: aktuální přehled. Vnitř Lék 2016; 62(10): 805–813.
Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ 2002; 325(7368): 828–831.
Junqueira DR, Zorzela LM, Perini E. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev 2017; 4: CD007557. Dostupné z DOI: <http://doi:10.1002/14651858.CD007557.pub3>.
Matýšková M. Warfarin, potrava a potravinové doplňky. Interní Med 2010; 12(2): 87–91. Dostupné z WWW: <https://www.internimedicina.cz/pdfs/int/2010/02/07.pdf>.
Samuelson BT, Cuker A, Siegal DM et al. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants. Chest 2017; 151(1): 127–138. Dostupné z DOI: <http://dx.doi.org/10.1016/j.chest.2016.08.1462>.
Baglin T, Barrowcliffe TW, Cohen A et al. for the British Committee for Standards in Haematology. Guidelines on the use and monitoring of heparin. Br J Haematol 2006; 133(1): 19–34. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2141.2005.05953.x>.
Salmonson T, Dogné JM, Janssen H et al. Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future. Views from a workshop at the European Medicines Agency (EMA). Eur Heart J Cardiovasc Pharmacother 2017; 3(1): 42–47. Dostupné z DOI: <http://dx.doi.org/10.1093/ehjcvp/pvw032>.
Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag 2016; 12: 35–44. Dostupné z DOI: <http://dx.doi.org/10.2147/VHRM.S89130>.
Ansell JE, Bakhru SH, Laulicht BE et al. Single-dose ciraparantag safely and completely reverse anticoagulant effects of edoxaban. Thromb Haemost 2017; 117(2): 238–245. Dostupné z DOI: <http://dx.doi.org/10.1160/TH16–03–0224>.
Nielsen PB, Skjøth F, Søgaard M et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017; 356: j510. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.j510>.